November 16, 2023 News by Andrea Lobo, PhD Probiotic eased pain and fatigue in RRMS, trial data show A commercial probiotic supplement containing the yeast Saccharomyces boulardii significantly eased pain and fatigue, and improved mental health and quality of life, in people with relapsing-remitting multiple sclerosis (RRMS), according to data from a clinical trial in Iran. The probiotic, BioDigest, also reduced inflammation and oxidative stress, a form…
August 16, 2023 News by Lindsey Shapiro, PhD Engineered probiotic found to ease symptoms in mouse model of MS A lab-engineered probiotic, composed of live bacteria that colonize the gut, was able to ease signs of disease in a mouse model of multiple sclerosis (MS), according to recent research. After discovering that a metabolite called lactate could activate immune signaling pathways that help to curb autoimmunity, scientists specifically…
August 23, 2021 Columns by Ed Tobias MS News That Caught My Eye Last Week: Ocrevus, Probiotics, Floodlight App, Sativex in UK Trial Will Test Ocrevus on Arm, Hand Function in PPMS A lot of the focus in MS treatment and clinical trials is placed on walking ability. It seems to me that only recently has attention been paid to above-the-waist disabilities. I know that many people with MS have problems…
August 17, 2021 News by Marisa Wexler, MS Probiotics Likely To Be of Help With RRMS, Meta-analysis Finds Probiotic supplements could ease disability, lessen depression, and improve overall health in people with relapsing-remitting multiple sclerosis (MS), according to an analysis of four randomized clinical trials. Physicians working with these patients might recommend “confirmed probiotic supplements” to help manage “MS concerns,” its scientists wrote, while noting that studies…
October 22, 2020 News by Marta Figueiredo, PhD Impact of Gut Microbiota in MS More Complex Than Thought, Study Shows The presence of a particular gut bacterium widely used in probiotics, called Lactobacillus reuteri (L. reuteri), was sufficient to increase disease severity in a mouse model of multiple sclerosis (MS), but only in genetically susceptible animals, a recent study shows. These findings highlight the complex interactions between…
March 4, 2020 News by Ana Pena PhD #ACTRIMS2020 – 3 Ways to Treat MS by Altering Gut Microbiome Under Study Modulating the bacteria that reside in the gut by treatingĀ multiple sclerosis (MS) patients with probiotics, fecal transplants, or gut-related microRNAs may help to ease inflammation and disease severity,Ā researchers withĀ Brigham and Women’s Hospital suggest. Howard Weiner, MD, a group leader at the hospital, presented his team’s findings on…
January 13, 2020 Columns by Ed Tobias MS News that Caught My Eye Last Week: AHSCT Trial Enlisting, Interferon-beta and Pregnancy, Probiotics, Language and Brain Health New Trial Compares Stem Cell Treatment to Available Therapies for Severe Relapsing MS This is a biggie. The U.S. National Institutes of Health is conducting a head to head study comparing autologous hematopoietic stem cell transplantation (AHSCT) to the high-efficacy, disease-modifying therapies currently being used: Tysabri, Lemtrada, Ocrevus, and…
January 7, 2020 News by Marta Figueiredo, PhD Probiotics Show Potential to Prevent, Delay Development of MS, Study Finds Probiotics show potential to prevent and delay the development of multiple sclerosis (MS) by changing immune and inflammatory responses, according to a review study. Data further support the link between the gutāsĀ microbial community (microbiota) and the central nervous system (brain and spinal cord), and neurodegenerative diseases. However, large-scale clinical…
September 27, 2019 News by Marisa Wexler, MS ExeGi Pharma’s Probiotic Visbiome Will Be Tested in MS Clinical Trial ExeGi Pharma announced a new clinical trial testing its probiotic Visbiome in people with multiple sclerosis (MS). The study will further evaluate whether changing bacteria in the gut could be therapeutically beneficial in MS. The human body hosts millions upon millions of bacterial guests, the majority of which…
January 15, 2018 News by Patricia Silva, PhD Probiotics Increase Punch of Treatments That Decrease Inflammation in MS, Study Shows Probiotics increased the punch of treatments that decrease the inflammation associated with multiple sclerosis, a study found. Using the supplements to add helpful bacteria to the gut may be a way to improve patients’ Ā outcomes, researchers added. The team from Harvard University-affiliated Brigham and Womenās Hospital did not…
September 18, 2017 Columns by Ed Tobias MS News That Caught My Eye: Probiotics, Gut Bacteria, Ocrevus, and a Pain Pill Probiotics Consumption May Improve Certain Disease Parameters in MS Patients, Study Suggests Probiotics (bacteria that help move food through your gut)Ā have been used for years to help treat stomach disorders such as irritable bowel syndrome, inflammatory bowel disease, and some types of diarrhea. More recently, researchers have…
September 15, 2017 News by Patricia Inacio, PhD Probiotics Consumption May Improve Certain Disease Parameters in MS Patients, Study Suggests Probiotics may improve the health of people with multiple sclerosis (MS) by reducing disability and improving inflammatory and metabolic parameters, an Iranian study shows. Live microorganisms linked to health benefits, known as probiotics, have long been known to help chronic disease patients. In a previous study of people with major depressive disorder, probiotics treatment for eight weeks improved patientsā depression and metabolic parameters. More recently, authors investigated the impact of probiotics on a group of MS patients, looking not only at mental health and metabolic indicators, but also disability scores. Researchers at Tehran's Shahid Beheshti Hospital recruited 60 MS patients, divided them in half, and assigned 30 to take a probiotic capsule and 30 a placebo once a day for 12 weeks. The probiotic contained the healthy bacteria Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum and Lactobacillus fermentum. Researchers measured patientsā health parameters and disability scores at baseline and after treatment. The results showed that probiotic intake after 12 weeks improved MS patients' disability scores (assessed by the expanded disability status scale, EDSS) when compared to placebo controls. Although this improvement was statistically significant, it was not clinically significant ā which is defined as a change of 1.0 point or more at EDSS levels less than 5.5, or 0.5 point or more at EDSS levels greater than 5.5). Moreover, benefits were also detected in several mental health parameters ā Beck Depression Inventory, general health questionnaire-28 (GHQ-28), depression anxiety and stress scale. Consuming probiotic capsules also significantly decreased insulin levels and high-density lipoprotein (HDL) cholesterol in circulation, researchers also found. It also lowered certain markers of inflammation and oxidative stress, such as serum high-sensitivity C-reactive protein (hs-CRP) and malondialdehyde (MDA).
July 14, 2017 News by Patricia Inacio, PhD High Levels of Pro-Inflammatory Immune Cells in Intestines May Promote MS Activity, Study Reports People with multiple sclerosis have high levels of pro-inflammatory TH17 immune cells in their intestines that correlate with change in the micro-organism mix in their gut and the levels of their disease activity, a study reports. Researchers said the findings suggest that diet, probiotics and therapies that regulate TH17 cells could help treat MS. Probiotics are supplements containing beneficial bacteria. The study, āHigh frequency of intestinal TH17 cells correlates with microbiota alterations and disease activity in multiple sclerosis,ā was published in the journal Science. Research has shown that TH17 cells, also known as T helper 17 cells, play a role in the development of MS. In fact, they were the first harmful immune T-cells to infiltrate the central nervous system, according to studies in animals Where TH17 cells become activated has been unclear, however. Studies in mice suggested it was mainly in the small intestine. Research has also indicated that their activation increases the potential for a person to develop an autoimmune brain disease like multiple sclerosis. An autoimmune disease occurs when the immune system, which defends the body against disease, decides that a person's healthy cells are foreign, and attacks those cells. Researchers decided to see if the findings in mouse models of MS applied to people with the disease. They discovered a link between higher levels of TH17 cells in MS patients' intestines and autoimmune brain problems. They also found a correlation between higher levels of TH17 cells and changes in patients' gut microbiome. The team then identified which bacteria were changing in the gut. Patients with increased levels of TH17 cells and higher disease activity had a higher ratio of Firmicutes to Bacteroidetes bacteria and more Streptococcus strains in their gut, particularly Streptococcus mitis and Streptococcus oralis. Previous studies have shown that these species promote TH17 cell differentiation in humans. Cell differentiation involves a cell transforming from one cell type to another ā usually a more specialized type. This dramatically changes a cell's size, shape, metabolic ā or fuel-burning ā activity, and responsiveness to signals. Some studies have suggested a link between T-cell differentiation and brain autoimmune diseases. āOn the basis of our findings, we speculate that, under certain conditions, or because of still unknown virulence factors, these Streptococcus strains can colonize the small intestine and favor TH17 cell differentiation in the human gut mucosa [linings],ā researchers wrote. In addition to more Streptococcus bacteria, the team detected lower levels of Prevotella bacteria in MS patients with disease activity than in healthy controls or patients with no disease activity. This decrease may also promote TH17 cell differentiation because āPrevotella is capable of producing the anti-inflammatory metabolite propionate that limits intestinal TH17 cell expansion in mice," the researchers wrote. Overall, the team concluded that āour data demonstrate that brain autoimmunity is associated with specific microbiota modifications and excessive TH17 cell expansion in the human intestine.ā The findings suggest that regulating TH17 cell expansion, along with changes in diet aimed at regulating intestinal linings, could be ways to help treat MS.
February 28, 2017 News by Laura Kolaczkowski #ACTRIMS2017 – MS, the Gut and Probiotics Harold Weiner, MD, believes in using probiotics to help treat multiple sclerosis.Ā He is such a believer that he did a presentation on the subject ā “Probiotics in Multiple Sclerosis” ā at the just-concluded Americas for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2017 Forum in Orlando. The event…
February 13, 2017 Columns by Debi Wilson Naturopathic Approach Has Made Gains in Quest to Lose Weight For many years I have been fighting the battle of the bulge while trying to decipher and combat many food intolerances. Every year I seem to come up short in the battle with losing weight, but I continue to try to shed the pounds. There are many challenges…
July 25, 2016 News by Patricia Silva, PhD Gut Bacteria and Multiple Sclerosis: What We Already Know, and What We’ve Still to Learn Gut bacteria and health have been topics of considerable scientific speculation in recent years,Ā and the field of multiple sclerosis (MS) research is no exception. But what do we really know about MS and our intestinal inhabitants? A review,Ā āEmerging Concepts on the Gut Microbiome and Multiple Sclerosis,āĀ published in…